The publication detail shows the title, authors (with indicators showing other profiled authors), information on the publishing organization, abstract and a link to the article in PubMed. This abstract is what is used to create the fingerprint of the publication. If any grants are referenced by the publication, they will be listed here as well.
A beta amyloidogenesis: unique, or variation on a systemic theme?
R Kisilevsky; P E Fraser (Profiled Author: Fraser, Paul E)
Department of Pathology, Queen's University, Kingston, Ontario Canada.
Critical reviews in biochemistry and molecular biology 1997;32(5):361-404.
For more than a century amyloid was considered to be an interesting, unique, but inconsequential pathologic entity that rarely caused significant clinical problems. We now recognize that amyloid is not one entity. In vivo it is a uniform organization of a disease, or process, specific protein co-deposited with a set of common structural components. Amyloid has been implicated in the pathogenesis of diseases affecting millions of patients. These range from Alzheimer's disease, adult-onset diabetes, consequences of prolonged renal dialysis, to the historically recognized systemic forms associated with inflammation and plasma cell disturbances. Strong evidence is emerging that even when deposited in local organ sites significant physiologic effects may ensue. With emphasis on A beta amyloid, we review the present definition, classification, and general in vivo pathogenetic events believed to be involved in the deposition of amyloids. This encompasses the need for an adequate amyloid precursor protein pool, whether precursor proteolysis is required prior to deposition, amyloidogenic amino acid sequences, fibrillogenic nucleating particles, and an in vivo microenvironment conducive to fibrillogenesis. The latter includes several components that seem to be part of all amyloids. The role these common components may play in amyloid accumulation, why amyloids tend to be associated with basement membranes, and how one may use these findings for anti-amyloid therapeutic strategies is also examined.
This section shows information related to the publication - computed using the fingerprint of the publication - including related publications, related experts and related grants with fingerprints representing significant amounts of overlap between their fingerprint and this publication. The red dots indicate whether those experts or terms appear within the publication, thereby showing potential and actual connections.
GANDY, SAMUEL E
20 September 1992 - 31 July 1995
NATIONAL INSTITUTE ON AGING
Total Funding: $ 544,235
2 September 2011 - 30 June 2014
FOGARTY INTERNATIONAL CENTER
Total Funding: $ 70,352
1 January 1990 - 31 August 2006
NATIONAL INSTITUTE ON AGING
Total Funding: $ 4,063,685
Michel Goedert; Maria Grazia SpillantiniScience (New York, N.Y.) 2006;314(5800):777-81.
Valérie Vingtdeux; Malika Hamdane; Marie Gompel; Séverine Bégard; Hervé Drobecq; Antoine Ghestem; Marie-Eve Grosjean; Vesna Kostanjevecki; Pierre Grognet; Eugeen Vanmechelen; et al.Neurobiology of disease 2005;20(2):625-37.
Lap Ho; Weiping Qin; Patrick N Pompl; Zhongmin Xiang; Jun Wang; Zhong Zhao; Yuanzhen Peng; Gina Cambareri; Anne Rocher; Charles V Mobbs; et al.FASEB journal : official publication of the Federation of American Societies for Experimental Biology 2004;18(7):902-4.
Appears in this Publication
Author of this Publication